In 2019, Mesoblast Ltd (MSB) plans to work diligently with the U.S. Food and Drug Administration (FDA) to submit a rolling Biologics License Application for use of remestemcel-L in treating acute graft versus host disease (aGVHD) in children, and will execute on the product candidate’s market access and commercialization strategyhttp://crweworld.com/article/news-provided-by-globenewswire/930707/mesoblast-highlights-2019-key-priorities-for-its-leading-cellular-medicines-pipeline-at-biotech-showcase-in-san-francisco
- Forums
- ASX - By Stock
- MSB
- Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase
MSB
mesoblast limited
Add to My Watchlist
0.62%
!
$1.61

Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.61 |
Change
-0.010(0.62%) |
Mkt cap ! $2.050B |
Open | High | Low | Value | Volume |
$1.61 | $1.62 | $1.57 | $3.037M | 1.906M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 40303 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.61 | 35684 | 40 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
19 | 40623 | 1.605 |
25 | 82614 | 1.600 |
14 | 88012 | 1.595 |
14 | 182367 | 1.590 |
15 | 91948 | 1.585 |
Price($) | Vol. | No. |
---|---|---|
1.610 | 33218 | 40 |
1.615 | 54845 | 25 |
1.620 | 177228 | 20 |
1.625 | 59501 | 10 |
1.630 | 361118 | 6 |
Last trade - 12.36pm 08/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online